In one paragraphArticle in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
17 authors at 4 institutions in 2 countries.
Katerina RademacherGladstone Institute for Neurological Disease, Gladstone Institutes, San Francisco, CA.ORCID 0000-0001-9676-6673 Dominik HaddadGladstone Institute for Neurological Disease, Gladstone Institutes, San Francisco, CA.ORCID 0009-0001-9354-7747 Aphroditi MamaligasGladstone Institute for Neurological Disease, Gladstone Institutes, San Francisco, CA.ORCID 0000-0002-9733-6285 Rose B CreedAligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD.ORCID 0000-0003-4893-2010 Zac ChattertonAligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD.ORCID 0000-0002-6683-1400 YuHong FuAligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD.ORCID 0000-0003-4539-2039 Joseph H GarciaGladstone Institute for Neurological Disease, Gladstone Institutes, San Francisco, CA.ORCID 0000-0002-7127-9534 Victoria VanceGladstone Institute for Neurological Disease, Gladstone Institutes, San Francisco, CA.ORCID 0000-0003-4546-5445 Anatol KreitzerGladstone Institute for Neurological Disease, Gladstone Institutes, San Francisco, CA.ORCID 0000-0001-7423-2398 Glenda M HallidayAligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD.ORCID 0000-0003-0422-8398 Alexandra B NelsonGraduate Program in Neuroscience, University of California San Francisco, San Francisco , CA.ORCID 0000-0002-9305-5662 Elyssa B MargolisGraduate Program in Neuroscience, University of California San Francisco, San Francisco , CA.ORCID 0000-0001-8777-302X Gladstone Institutes · USThe University of Sydney · AUUniversity of California, San Francisco · USNortheastern University · US
Funding
Understand and probing disrupted glucose metabolism in Alzheimer's diseaseRF1AG064170 · NIA · J. DAVID GLADSTONE INSTITUTES · PI CHAUMEIL, MYRIAM MARIANNE, NAKAMURA, KEN · 2019 to 2019
$3.6MDetermining how neural activity impairs bioenergetics in PD pathogenesisR01NS091902 · NINDS · J. DAVID GLADSTONE INSTITUTES · PI NAKAMURA, KEN · 2015 to 2019
$2.1MHeterogeneity of Ventral Tegmental Area Neurons and Opioid RewardR01DA030529 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MARGOLIS, ELYSSA · 2011 to 2015
$1.8MNeural circuits underlying motor impairments in a rodent model of progressive supranuclear palsyK00NS108458 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CREED, ROSE BERTHE · 2020 to 2023
$320kUnderstanding how neuronal glucose metabolism changes in AD due to ApoE4F32AG082460 · NIA · J. DAVID GLADSTONE INSTITUTES · PI SEI, YOSHI · 2023 to 2025
$240kElucidating the Role of Neural Activity in Midbrain Dopamine Neuron DegenerationF31NS137765 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Katerina Rademacher · 2024 to 2026
$132kNIA NIH HHS F32 AG082460NIA NIH HHS RF1 AG064170NIDA NIH HHS R01 DA030529NINDS NIH HHS F31 NS137765NINDS NIH HHS K00 NS108458NINDS NIH HHS R01 NS091902Wellcome Trust
6 · The paper itselfAbstract
Parkinson's disease (PD) is characterized by the death of substantia nigra (SNc) dopamine (DA) neurons, but the pathophysiological mechanisms that precede and drive their death remain unknown. The activity of DA neurons is likely altered in PD, but we understand little about if or how chronic changes in activity may contribute to degeneration. To address this question, we developed a chemogenetic (DREADD) mouse model to chronically increase DA neuron activity, and confirmed this increase using
Identifiers
PMID38645054
PMCPMC11030348
OpenAlexW4394692897
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390